Summit Therapeutics (SMMT) Invested Capital (2018 - 2026)

Summit Therapeutics has reported Invested Capital for 9 years, with the latest figure at $545.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 58.55% year-over-year to $545.9 million; the trailing twelve-month figure through Mar 2026 stood at $545.9 million (up 58.55% YoY), and the FY2025 full-year result was $658.9 million, up 69.48% from the prior year.
• Invested Capital for Q1 2026 stood at $545.9 million, down from $658.9 million in the prior quarter.
• The five-year high for Invested Capital was $658.9 million in Q4 2025, with the low at $44.2 million in Q1 2024.
• Historically, Invested Capital has averaged $227.8 million across 5 years, with a median of $133.5 million in 2023.
• Annual changes were most pronounced in 2024 — Invested Capital slumped 66.88% — and 2025, when it jumped 678.85%.
• Summit Therapeutics' Invested Capital stood at $126.7 million in 2022, then tumbled by 38.66% to $77.7 million in 2023, then jumped by 400.37% to $388.7 million in 2024, then soared by 69.48% to $658.9 million in 2025, then fell by 17.14% to $545.9 million in 2026.
• The last three Invested Capital figures came in at $545.9 million (Q1 2026), $658.9 million (Q4 2025), and $192.3 million (Q3 2025), per Business Quant data.